Oculis lists at Nasdaq through SPAC merger
The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
There is increasing interest in delivering a range of drugs via inhalation because of the benefits it can offer patients. Lonza’s Kim Shepard looks at the advantages of pulmonary delivery, and the prospect for inhaled biologics.
The fourth fund of High-Tech Gründerfonds has reached a final fund volume of €493.8m
British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
Interferon-gamma overexpression leads to hypertension-induced damage to the blood-brain barrier by reprogrammed macrophages.
French Abivax SA has raised €130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.
Myoglobin producer Paleo NV has closed a € 12 m Series A round led by DSM Venturing and Planet A Ventures.
CDMO Minaris Regenerative Medicine GmbH is to manufacture the leukocyte infusion therapy N-LIfT for LIFT BioSciences.
PVH Corp has joined fiber-to-fiber consortium that wants to make textile recycling sustainable by establishing standards for biorecycled textile fibre.